Square Pharmaceuticals PLC. Stock

Equities

SQURPHARMA

BD0473SQPH00

Pharmaceuticals

End-of-day quote Dhaka S.E. 06:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
214.1 BDT -0.28% Intraday chart for Square Pharmaceuticals PLC. -1.56% +1.81%
Sales 2024 * 71.99B 655M Sales 2025 * 81.08B 737M Capitalization 190B 1.73B
Net income 2024 * 21.5B 195M Net income 2025 * 24.67B 224M EV / Sales 2024 * 2.64 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.34 x
P/E ratio 2024 *
8.96 x
P/E ratio 2025 *
7.69 x
Employees 12,503
Yield 2024 *
4.79%
Yield 2025 *
5.25%
Free-Float 64.82%
More Fundamentals * Assessed data
Dynamic Chart
Square Pharmaceuticals PLC. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Square Pharmaceuticals PLC. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Square Pharmaceuticals PLC. Recommends Cash Dividend for the Year Ended June 30, 2023 CI
Square Pharmaceuticals PLC Announces Contract Manufacturing Agreement with M/S Aristopharma Ltd CI
Square Pharmaceuticals Limited has Changed its Name to Square Pharmaceuticals PLC CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022 CI
Square Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021 CI
Square Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2021 CI
Square Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended on June 30, 2021 CI
Square Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended March 31, 2021 CI
Square Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended December 31, 2020 CI
Square Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2020 CI
More news
1 day-0.28%
1 week-1.56%
Current month-1.65%
1 month-0.65%
3 months+0.99%
6 months+1.81%
Current year+1.81%
More quotes
1 week
213.90
Extreme 213.9
217.40
1 month
213.90
Extreme 213.9
218.80
Current year
209.50
Extreme 209.5
222.70
1 year
209.50
Extreme 209.5
222.70
3 years
204.30
Extreme 204.3
251.90
5 years
149.05
Extreme 149.0476
251.90
10 years
131.59
Extreme 131.5852
278.67
More quotes
Managers TitleAgeSince
Chief Executive Officer - 79-12-31
Director of Finance/CFO - -
Compliance Officer - -
Members of the board TitleAgeSince
Chief Executive Officer - 79-12-31
Chairman - 90-12-31
Director/Board Member - 90-12-31
More insiders
Date Price Change Volume
24-04-18 214.1 -0.28% 252,001
24-04-17 214.7 -0.19% 233,358
24-04-16 215.1 -0.42% 321,031
24-04-15 216 -0.69% 352,833

End-of-day quote Dhaka S.E., April 17, 2024

More quotes
Square Pharmaceuticals PLC. is a Bangladesh-based pharmaceutical company. The Company's products include pharma, herbal and nutraceutical, and agrovet and crop care. The Company's pharma products include Ace, Ace Plus, Ace Power, Aclitol Cozycap, Adryl, Acetram, Afun, Akicin, Alacot DS Eye Drops, Alacot Eye Drops, Alacot Max Eye Drops, Alarid Eye Drops, Alarid, Alice Lotion, Amodis 500 IV, Asynta Max, Avaspray, Axlovir Combipack, Ansulin Pen Cartridge, Angilock Plus, Clopirox Cream, Clopirox Shampoo, Contilex TS, Germisol Hand Rub, Glycovent Nebuliser Solution, Glysup, Gynepro and K-One MM. Its herbal and nutraceutical products include AmCivit, Antiscar, Arubin, Betaburn, Bioprem, Bolardi, Femony, Fitvit, Flemo Max, Flemo, Flemo Plus, Freezy, Lecor, Livolite, Maximilk, Monera, Redclov, Reli Balm, Revatol, Toco Soft, Torel, Trumega and ZanthinTM Softgel Capsule. Its agrovet and crop care products include Ace-Vet Bolus, Agrizeb 80 WP, Aqua Rock, Almex-Vet Bolus and Andopan Powder.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
214.1 BDT
Average target price
321.8 BDT
Spread / Average Target
+50.28%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. SQURPHARMA Stock